Compared to cisplatin treatment-naive bladder cancer, cisplatin-treated cancer has relatively higher MAT2A expression, lower circARHGAP10 expression and higher histone methylation level(Fig. S7E, F).In two PDX models, knocking down circARHGAP10 with cholesterol-conjugated si-circRNA [34] (Fig. 5F) increased cisplatin resistance of the cisplatin treatment naive BCa tissue (Fig. 5G, H) and the protein expression of MAT2A, CD44 and Ki-67 (Fig. 5I). This evidence concerns the gene MAT2A and urinary bladder carcinoma.